Table 3 Treatments and outcomes of hospitalized patients with COVID-19.
Characteristic (N = 434) | N | Value | Disease severity category† | |||
|---|---|---|---|---|---|---|
Asymptomatic/mild (n = 54) | Moderate (n = 196) | Severe (n = 99) | Critically ill (n = 68) | |||
Therapies | ||||||
Antibacterial therapy | 434 | 346 (79.7) | 22/54 (40.7) | 176/196(89.8) | 79/99 (79.8) | 66/68 (97.1) |
Antifungal therapy | 434 | 10 (2.3) | 1/54 (1.9) | 1/196 (0.5) | 6/99 (6.1) | 2/68 (2.9) |
Anti-inflammatory therapy | ||||||
IL inhibitors | 434 | 3 (0.7) | 0/54 (0.0) | 0/196 (0.0) | 1/99 (1.0) | 2/68 (2.9) |
Corticosteroids | 434 | 65 (15.0) | 5/54 (9.3) | 26/196 (13.3) | 14/99 (14.1) | 19/68 (27.9) |
Hydroxychloroquine | 434 | 171 (39.4) | 4/54 (7.4) | 73/196 (37.2) | 46/99 (46.5) | 47/68 (69.1) |
Antiviral therapy | ||||||
Lopinavir | 434 | 3 (0.7) | 0/54 (0.0) | 0/196 (0.0) | 2/99 (2.0) | 1/68 (1.5) |
Remdesivir | 434 | 1 (0.2) | 0/54 (0.0) | 0/196 (0.0) | 0/99 (0.0) | 1/68 (1.5) |
Renal therapy∆ | 434 | 13 (3.0) | 0/54 (0.0) | 3/196 (1.5) | 2/99 (2.0) | 6/68 (8.8) |
Vasopressor use | 421 | 26 (6.2) | 0/43 (0.0) | 7/195 (3.6) | 5/98 (5.1) | 14/68 (20.6) |
Other therapy | 397 | 175 (44.1) | 27/50 (54.0) | 59/175 (33.7) | 35/93 (37.6) | 51/62 (82.3) |
Outcome parameters | ||||||
30-day mortality | 423 | 75 (17.7) | 3/43 (7.0) | 18/196 (9.2) | 19/99 (19.2) | 32/68 (47.1) |
90-day mortality | 423 | 85 (20.1) | 5/43 (11.6) | 23/196 (11.7) | 21/99 (21.2) | 33/68 (48.5) |
Hospital mortality | 423 | 80 (18.9) | 4/43 (9.3) | 21/196 (10.7) | 20/99 (20.2) | 32/68 (47.1) |
Hospital length of stay, median (IQR) days | 423 | 8 (4.7–14.0) | 7.0 (2.5–13.0) | 7.9 (5.0–12.9) | 10.0 (5.9–12.9) | 12.0 (6.0–23.5) |
ICU admission ever | 434 | 85 (19.6) | 1/54 (1.9) | 22/196 (11.2) | 21/99 (21.2) | 40/68 (58.8) |
ICU length of stay⃰, median (IQR) days | 84 | 7.2 (3.0–16.0) | 4.0 (4.0–4.0) | 3.8 (1.1–11.2) | 6.8 (4.6–31.2) | 8.5 (5.4–18.3) |
ICU-mortality* | 85 | 21 (24.7) | 0/1 (0.0) | 5/22 (22.7) | 3/21 (14.3) | 12/40 (30.0) |
